BioNTech SE
Innovative immunotherapies fighting diseases
- B2B
- B2G
- Has physical offices
- Publicly traded
- Healthtech
- Sales-led purchase
About BioNTech SE
Development of novel immunotherapies leveraging mRNA technology to combat cancer and infectious diseases, improving global health outcomes.
Key facts
- Industry
- Biotechnology Research
- Company size
- 5,001–10,000 employees
- Headquarters
- Mainz, Rhineland-Palatinate, Germany
- Founded
- 2008
- Revenue
- $56.3M – $445MTamtam estimate
- Website
- biontech.com
- linkedin.com/company/biontech-se
Jobs at BioNTech SE
- Manager Global Quality Systems - Pharma Compliance
- Director Manufacturing Sciences & Technology
- Associate Director, Procurement - US Commercial & Medical
- Director Program & Production Procurement CDMO / CMO
- Senior Director External Manufacturing QA
- Manager GxP Compliance Management Mainz (m/w/d)
- (Associate Director) Senior Scientist Manufacturing global MS&T
- Associate Director, CMC Manufacturing Technologies
BioNTech SE in the news
- BioNTech's Founders Map a Breakaway Venture as German Plants Face the Axe
BioNTech is undergoing major changes, including the departure of two founders to start a new company, the closure of three German production sites, ongoing mRNA patent lawsuits, and executive share sales.
- BioNTech SE: Moving Past Covid (NASDAQ:BNTX)
BioNTech SE is shifting its focus to an oncology pipeline with 33 trials and $19 billion in cash, with pivotal data for its key drug expected after 2028.
- BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading
BioNTech is closing three German sites, reported updated positive trial data for gotistobart, and its stock traded at EUR 86.10 over the weekend.
- BioNTech stock faces a 59.5 percent Q2 revenue drop
BioNTech experienced a significant 59.5% Q2 2026 revenue decline and a loss per share of USD 2.53, yet analysts maintain a "Moderate Buy" consensus with a target price of USD 126.00.
- BioNTech meldet neue Gotistobart-Daten. BioNTech-Aktie kostet 86,10 Euro
BioNTech and OncoC4 released updated Gotistobart data from their Phase 3 study, showing an improved median overall survival of 18.5 months.
BioNTech SE at a glance
BioNTech SE is a B2B/B2G company in the Biotechnology Research industry, headquartered in Mainz, Rhineland-Palatinate, Germany.
BioNTech SE was founded in 2008.
BioNTech SE has 5,001–10,000 employees.
BioNTech SE's revenue is $56.3M – $445M (Tamtam estimate).
BioNTech SE is hiring: 8 recent open roles, including Manager Global Quality Systems - Pharma Compliance, Director Manufacturing Sciences & Technology, Associate Director, Procurement - US Commercial & Medical.
Selling to companies like BioNTech SE?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies